• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, August 18, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

More than 40% of status epilepticus patients suffer adverse outcomes

Bioengineer by Bioengineer
January 24, 2020
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Mortality risk can be estimated already in the emergency room

IMAGE

Credit: Reetta Kälviäinen


A new study published in Seizure gives insight into the short-term outcome of patients treated for status epilepticus in Kuopio University Hospital in Finland. The researchers found a 9% risk of death and a 32% risk of functional loss at one month after status epilepticus. The patient’s risk of death could be predicted relatively reliably already in the emergency room by using status epilepticus-related prognostic tools.

The study, conducted by the University of Eastern Finland and the Epilepsy Centre in Kuopio University Hospital, enrolled 137 status epilepticus patients during 2015. Fourteen patients were enrolled twice because of another episode of status epilepticus during the study period. The outcome was assessed at one month after hospital discharge by means of a phone interview and a patient record review.

The prognostic scores STESS (Status Epilepticus Severity Score) and EMSE (Epidemiology-based Mortality score in Status Epilepticus) proved themselves useful in mortality prediction. They were both able to predict survival with over 95% certainty in many episodes of status epilepticus with low risk features. The scores are simple enough to be calculated in the emergency room. They require information about the etiology and clinical presentation of status epilepticus, and the age and comorbidities of the patient.

Status epilepticus is a prolonged epileptic seizure that lasts for more than 30 minutes. Status epilepticus is a life-threatening emergency which requires rapid treatment. Any epileptic seizure lasting longer than 5 minutes is treated as an early status epilepticus. Status epilepticus can occur even without a prior diagnosis of epilepsy.

###

For further information, please contact:

Researcher Joni Sairanen joni.sairanen (at) fimnet.fi

Professor Reetta Kälviäinen reetta.kalvianen (at) uef.fi, tel. +358405839249

Article (in Press): J. Sairanen, A-M. Kantanen, H. Hyppölä, R. Kälviäinen. Outcome of status epilepticus and the predictive value of the EMSE and STESS scores: a prospective study. Seizure: European Journal of Epilepsy 75 (2020) 115-120. DOI: https://doi.org/10.1016/j.seizure.2019.12.026

Media Contact
Reetta Kälviäinen
[email protected]
358-405-839-249

Related Journal Article

http://dx.doi.org/10.1016/j.seizure.2019.12.026

Tags: Death/DyingMedicine/HealthMortality/Longevityneurobiology
Share12Tweet8Share2ShareShareShare2

Related Posts

blank

University of Houston Scientist Develops Innovative Drug Delivery System to Combat Lupus

August 18, 2025
Decoding microRNA Regulation in T Cells Efficiently

Decoding microRNA Regulation in T Cells Efficiently

August 18, 2025

Promising Outcomes from Phase I/II Gene Therapy Trial for GM2 Gangliosidosis, Including Tay-Sachs and Sandhoff Diseases

August 18, 2025

DENND1A Drives Testosterone in Polycystic Ovary Syndrome

August 18, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Molecules in Focus: Capturing the Timeless Dance of Particles

    141 shares
    Share 56 Tweet 35
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    80 shares
    Share 32 Tweet 20
  • Modified DASH Diet Reduces Blood Sugar Levels in Adults with Type 2 Diabetes, Clinical Trial Finds

    59 shares
    Share 24 Tweet 15
  • Predicting Colorectal Cancer Using Lifestyle Factors

    47 shares
    Share 19 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Discovering the Brain’s Navigational Compass: New Insights into Human Navigation

Danforth Center Grants Proof-of-Concept Funding to Four Teams Driving Agricultural Innovation

University of Houston Scientist Develops Innovative Drug Delivery System to Combat Lupus

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.